Abstract
Early detection of HIV-1 infection is crucial to initiate anti-retroviral therapy (ART) to suppress viremia and disease progression. Herein, we developed a CRISPR/Cas12a-based HIV-1 detection assay by optimizing components for a coupled isothermal preamplification by recombinase polymerase amplification (RPA). The HIV-1 Indian Clade-C-specific conserved pol region was targeted by crRNA designed for Clade-specific detection. The CRISPR/Cas12a cleavage of the viral cDNA input is displayed as a single visually detectable outcome due to the collateral cleavage of the ssDNA-FAM-BQ reporter, enabling the rapid detection of HIV-1. The performance of the assay was evaluated by testing sera of 41 Indian Clade C HIV-1 seropositive individuals, which included 28 HIV-1 infected infant samples, HIV-1 Indian clade C genome plasmid, viral disease control DNA/RNA samples (Influenza, RSV, Parvovirus, HPIV, CMV, and HBV), and 31 healthy donor sera samples. With 96% sensitivity and 92.65% specificity for HIV-1C detection, with fluorescence and visual readout, and a capability of detection using lateral flow dipsticks, our CRISPR/Cas12a-based HIV-1 C detection assay demonstrates the potential to be developed into a robust point-of-care molecular diagnostic test for HIV-1C. Moreover, it may serve as a potential rapid NAT alternative in detecting mother-to-child transmission (MCT) of HIV-1C in infants (<2 years of age), where rapid antibody-based serology tests are rendered ineffective due to the presence of maternal antibodies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by The Department of Biotechnology (DBT), India (Project Code BT/GET/119/SP31652/2020)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee of All India Institute of Medical Sciences gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
